NeoGenomics, Inc. NEO
NASDAQ · United States · Health Services
$18.36-0.38 (-2.03%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 38.9% gain over the past six months, beating the S&P 500 by 20.9 percentage points.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.